Mohamad B Taha1, Neha Rao2, Muthiah Vaduganathan3, Miguel Cainzos-Achirica1,4, Khurram Nasir1,4, Kershaw V Patel5. 1. Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin St Suite 1801, Houston, TX, 77030, USA. 2. Department of Medicine, Houston Methodist Hospital, Houston, TX, USA. 3. Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 4. Center for Outcomes Research, Houston Methodist, Houston, TX, USA. 5. Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin St Suite 1801, Houston, TX, 77030, USA. kvpatel@houstonmethodist.org.
Abstract
PURPOSE OF REVIEW: Type 2 diabetes is frequently accompanied by obesity, nonalcoholic fatty liver disease, chronic kidney disease, and cardiovascular disease, which collectively contribute to the high burden of cardiometabolic disease. This review discusses cardiometabolic disease management, strategies to implement cardiometabolic centers to deliver care, and dedicated programs to train the next generation of cardiometabolic experts. RECENT FINDINGS: Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist have demonstrated beneficial effects across cardiometabolic conditions. However, utilization of effective pharmacotherapies is low in clinical practice, in part due to clinical inertia and traditional sharp delineation in clinical responsibilities of specialists. Multidisciplinary clinics and population-health models can provide comprehensive care but require investment in physical and information technology infrastructure as well as in training and accreditation. Post-internal medicine residency cardiometabolic health training programs have been proposed. Implementing cardiometabolic centers in health systems involves reshaping current practices. Training programs focused on cardiometabolic health are needed to address the growing burden of disease and specific training needs in this ever-expanding area.
PURPOSE OF REVIEW: Type 2 diabetes is frequently accompanied by obesity, nonalcoholic fatty liver disease, chronic kidney disease, and cardiovascular disease, which collectively contribute to the high burden of cardiometabolic disease. This review discusses cardiometabolic disease management, strategies to implement cardiometabolic centers to deliver care, and dedicated programs to train the next generation of cardiometabolic experts. RECENT FINDINGS: Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist have demonstrated beneficial effects across cardiometabolic conditions. However, utilization of effective pharmacotherapies is low in clinical practice, in part due to clinical inertia and traditional sharp delineation in clinical responsibilities of specialists. Multidisciplinary clinics and population-health models can provide comprehensive care but require investment in physical and information technology infrastructure as well as in training and accreditation. Post-internal medicine residency cardiometabolic health training programs have been proposed. Implementing cardiometabolic centers in health systems involves reshaping current practices. Training programs focused on cardiometabolic health are needed to address the growing burden of disease and specific training needs in this ever-expanding area.
Authors: Aidin Rawshani; Araz Rawshani; Stefan Franzén; Björn Eliasson; Ann-Marie Svensson; Mervete Miftaraj; Darren K McGuire; Naveed Sattar; Annika Rosengren; Soffia Gudbjörnsdottir Journal: N Engl J Med Date: 2017-04-13 Impact factor: 91.245
Authors: Suzanne V Arnold; James A de Lemos; Robert S Rosenson; Christie M Ballantyne; Yuyin Liu; Katherine E Mues; Shushama Alam; Mary Elliott-Davey; Deepak L Bhatt; Christopher P Cannon; Mikhail Kosiborod Journal: Circulation Date: 2019-06-07 Impact factor: 29.690
Authors: Aidin Rawshani; Araz Rawshani; Stefan Franzén; Naveed Sattar; Björn Eliasson; Ann-Marie Svensson; Björn Zethelius; Mervete Miftaraj; Darren K McGuire; Annika Rosengren; Soffia Gudbjörnsdottir Journal: N Engl J Med Date: 2018-08-16 Impact factor: 91.245
Authors: Christian A Schneider; Ele Ferrannini; Ralph Defronzo; Guntram Schernthaner; John Yates; Erland Erdmann Journal: J Am Soc Nephrol Date: 2007-12-05 Impact factor: 10.121
Authors: Muthiah Vaduganathan; Ravi B Patel; Avinainder Singh; Cian P McCarthy; Arman Qamar; James L Januzzi; Benjamin M Scirica; Javed Butler; Christopher P Cannon; Deepak L Bhatt Journal: J Am Coll Cardiol Date: 2019-04-02 Impact factor: 24.094
Authors: Darren K McGuire; Weichung J Shih; Francesco Cosentino; Bernard Charbonnel; David Z I Cherney; Samuel Dagogo-Jack; Richard Pratley; Michelle Greenberg; Shuai Wang; Susan Huyck; Ira Gantz; Steven G Terra; Urszula Masiukiewicz; Christopher P Cannon Journal: JAMA Cardiol Date: 2021-02-01 Impact factor: 14.676